CardioMech: Funding, Investors & Team (Sep 2026)
CardioMech, a developer of therapeutic devices for structural heart disease, offers a transcatheter solution for placing artificial chords in the mitral valve. These devices provide an alternative to cardiac surgery and allow surgeons to explore new therapeutic options for heart diseases. The technology aims to treat patients suffering from severe, symptomatic, degenerative mitral regurgitation (DMR) caused by prolapse or flail. Established in 2015, CardioMech is based in Trondheim, Norway.
CardioMech has raised $36.0M across 3 funding rounds on record, the most recent an undisclosed round of $13.0M announced in Jan 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CardioMech Company Profile and Key Stats
Latest funding round on record: Jan 2024.
CardioMech Funding Rounds
CardioMech raised $18.5M in an undisclosed round announced in Aug 2020.
2.5 years later, an undisclosed round of $4.5M was announced in Feb 2023.
11 months later, an undisclosed round of $13.0M was announced in Jan 2024.
CardioMech Founders and Leadership Team
Contact details for the CardioMech team: 2 of 2 have an email address on file.
Start 14-day free trial →CardioMech Funding Compared to Other Biotechnology Startups
CardioMech's latest round of $13.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CardioMech in Biotechnology and Trondheim
Companies Similar to CardioMech
Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on…
Hofseth BioCare's key goal is to offer high benefit added biomarine elements for human applications. Through…
Circio Holding ASA is a company in the clinical stage that is developing immune activators for challenging…
IDEX, a biometrics software and fingerprint authentication company based in Oslo, Norway, was established in…
Arctic Bioscience is a biotechnology research company that develops products, solutions, and technologies…
Lytix Biopharma AS is a privately-owned pharmaceutical company focussed on anti-microbials and cancer…
Actithera is a company specializing in developing radioligand therapies through the application of medicinal…
NoMy is a company focused on creating sustainable and scalable solutions for alternative proteins by…
Oncoinvent AS designs and develops cancer treatments by applying known physical and chemical principles of…
Biosergen AS develops variants of nystatin with improved properties. Its pipeline products include S44HP, an…
NEXT offers secure and user-friendly fingerprint sensor technology for verification purposes in various…
We are a speciality pharmaceutical business committed to the creation and marketing of goods for people who…
CardioMech Funding FAQs
What does CardioMech do?
CardioMech, a developer of therapeutic devices for structural heart disease, offers a transcatheter solution for placing artificial chords in the mitral valve. These devices provide an alternative to cardiac surgery and allow surgeons to explore new therapeutic options for heart diseases. The technology aims to treat patients suffering from severe, symptomatic, degenerative mitral regurgitation (DMR) caused by prolapse or flail. Established in 2015, CardioMech is based in Trondheim, Norway.
How much funding has CardioMech raised?
CardioMech has raised $36.0M across 3 rounds on record. The most recent is an undisclosed round of $13.0M announced in Jan 2024.
When did CardioMech last raise funding?
CardioMech's most recent funding round on record is an undisclosed round of $13.0M, announced in Jan 2024.
Who founded CardioMech?
FundedIQ lists Nikolai Hiorth (Founder) at CardioMech.
Who is the CEO of CardioMech?
Rick Nehm is listed as CEO at CardioMech.
Where is CardioMech headquartered?
CardioMech is based in Trondheim, Sor-Trondelag, Norway.
How many employees does CardioMech have?
CardioMech is in the 1-10 employee band.
How does CardioMech's funding compare to other Biotechnology startups?
CardioMech's latest round of $13.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's CardioMech Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CardioMech is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.